SCHEMBL7260503

SCHEMBL7260503

Cc1ccc(-c2n[nH]c3nnc(Cl)cc23)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 4/20 0.44
▸ ALDH1A1 P00352 4/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ MAP2K4 P45985 4/20 0.42
▸ MAPKAPK3 Q16644 3/20 0.42
▸ MAPK6 Q16659 3/20 0.42
▸ MAPKAPK2 P49137 2/20 0.42
▸ MAPKAPK5 Q8IW41 2/20 0.42
▸ KDM4E B2RXH2 3/20 0.40
▸ MAPT P10636 2/20 0.40
▸ HPGD P15428 1/20 0.40
▸ HSP90AB1 P08238 1/20 0.39
▸ HTR1D P28221 1/20 0.38
▸ HTR2A P28223 1/20 0.38
▸ HTR2C P28335 1/20 0.38
▸ HTR1E P28566 1/20 0.38
▸ HTR7 P34969 1/20 0.38
▸ HTR2B P41595 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7261133 0.84 ALDH1A1 (0.44) MAPK1ALDH1A1SMN1; SMN2MAP2K4MAPK6
SCHEMBL7259113 0.83 HPGD (0.47) ALDH1A1SMN1; SMN2MEN1KMT2AMAP2K4
SCHEMBL7256520 0.83 MEN1 (0.47) MAPK1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL7261231 0.77 GSK3A (0.50) MAPK1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL19244018 0.75 ADORA2A (0.34) —
SCHEMBL7256511 0.74 EGFR (0.47) MAPK1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL7255654 0.72 IDO1 (0.40) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL18513164 0.70 ALDH1A1 (0.44) MAPK1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL16517285 0.70 TDP1 (0.40) MAPK1KDM4EMAPT
SCHEMBL16516933 0.68 TDP1 (0.30) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003080616-A1 PYRAZOLOPYRIDAZINE DERIVATIVES, PROCESS FOR PREPARATION AND USE FOR THE INHIBITION OF GSK-3 GLAXO GROUP LIMITED (GB) 2003-10-02 — — WO disclosed
Send feedback